
The Pfizer Inc (NYSE:PFE) - BioNTech SE (NASDAQ:BNTX) vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15.
According to a study conducted by the Centers for Disease Control and Prevention (CDC) and Abt Associates, the shot showed 59% efficacy in those ages 12 to 15 and 31% in those ages 5 to 11.